{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:42:03Z","timestamp":1792028523965,"version":"4.4.0"},"reference-count":80,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2024.0064","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T09:56:27Z","timestamp":1720086987000},"source":"Crossref","is-referenced-by-count":43,"title":["Psoriasis as a systemic disease"],"prefix":"10.3238","author":[{"given":"Ulrich","family":"Mrowietz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Sondermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Gerdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Sewerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"10.3238\/arztebl.m2024.0064_ref1","doi-asserted-by":"crossref","unstructured":"Hagenstrom K, Muller K, Garbe C, Augustin M: Prevalence of psoriasis and psoriatic arthritis in Germany—analysis of claims data. J Dtsch Dermatol Ges 2024; 22: 45–54.","DOI":"10.1111\/ddg.15269"},{"key":"10.3238\/arztebl.m2024.0064_ref2","doi-asserted-by":"crossref","unstructured":"van de Kerkhof PC, Reich K, Kavanaugh A, et al.: Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol 2015; 29: 2002–10.","DOI":"10.1111\/jdv.13150"},{"key":"10.3238\/arztebl.m2024.0064_ref3","doi-asserted-by":"crossref","unstructured":"Mrowietz U, S\u00fcmb\u00fcl M, Gerdes S: Depression, a major comorbidity of psoriatic disease, is caused by metabolic inflammation. J Eur Acad Dermatol Venereol 2023; 37: 1731–8.","DOI":"10.1111\/jdv.19192"},{"key":"10.3238\/arztebl.m2024.0064_ref4","doi-asserted-by":"crossref","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J: Psoriasis. Lancet 2021; 397: 1301–15.","DOI":"10.1016\/S0140-6736(20)32549-6"},{"key":"10.3238\/arztebl.m2024.0064_ref5","doi-asserted-by":"crossref","unstructured":"Prinz I, Sandrock I, Mrowietz U: Interleukin-17 cytokines: Effectors and targets in psoriasis—a breakthrough in understanding and treatment. J Exp Med 2020; 217.","DOI":"10.1084\/jem.20191397"},{"key":"10.3238\/arztebl.m2024.0064_ref6","doi-asserted-by":"crossref","unstructured":"Cheuk S, Wik\u00e9n M, Blomqvist L, et al.: Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol 2014; 192: 3111–20.","DOI":"10.4049\/jimmunol.1302313"},{"key":"10.3238\/arztebl.m2024.0064_ref7","doi-asserted-by":"crossref","unstructured":"Puig L, Costanzo A, Mu\u00f1oz-El\u00edas EJ, et al.: The biological basis of disease recurrence in psoriasis: a historical perspective and current models. Br J Dermatol 2022; 186: 773–81.","DOI":"10.1111\/bjd.20963"},{"key":"10.3238\/arztebl.m2024.0064_ref8","doi-asserted-by":"crossref","unstructured":"Kim J, Moreno A, Krueger JG: The imbalance between Type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris. Front Immunol 2022; 13: 1005115.","DOI":"10.3389\/fimmu.2022.1005115"},{"key":"10.3238\/arztebl.m2024.0064_ref9","unstructured":"Kocaaga A, Kocaaga M: Psoriasis: An immunogenetic perspective. Glob Med Genet 2022; 9: 82–9."},{"key":"10.3238\/arztebl.m2024.0064_ref10","doi-asserted-by":"crossref","unstructured":"Kuiper JJ, Prinz JC, Stratikos E, et al.: EULAR study group on ‘MHC-I-opathy‘: identifying disease-overarching mechanisms across disciplines and borders. Ann Rheum Dis 2023; 82: 887–96.","DOI":"10.1136\/ard-2022-222852"},{"key":"10.3238\/arztebl.m2024.0064_ref11","doi-asserted-by":"crossref","unstructured":"Zhou W, Abdelrahman KM, Dey AK, et al.: Association among noncalcified coronary burden, fractional flow reserve, and myocardial injury in psoriasis. J Am Heart Assoc 2020; 9: e017417.","DOI":"10.1161\/JAHA.119.017417"},{"key":"10.3238\/arztebl.m2024.0064_ref12","doi-asserted-by":"crossref","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. Jama 2006; 296: 1735–41.","DOI":"10.1001\/jama.296.14.1735"},{"key":"10.3238\/arztebl.m2024.0064_ref13","doi-asserted-by":"crossref","unstructured":"Patrick MT, Li Q, Wasikowski R, et al.: Shared genetic risk factors and causal association between psoriasis and coronary artery disease. Nat Commun 2022; 13: 6565.","DOI":"10.1038\/s41467-022-34323-4"},{"key":"10.3238\/arztebl.m2024.0064_ref14","doi-asserted-by":"crossref","unstructured":"Elnabawi YA, Oikonomou EK, Dey AK, et al.: Association of biologic therapy with coronary inflammation in patients with psoriasis as assessed by perivascular fat attenuation index. JAMA Cardiol 2019; 4: 885–91.","DOI":"10.1001\/jamacardio.2019.2589"},{"key":"10.3238\/arztebl.m2024.0064_ref15","doi-asserted-by":"crossref","unstructured":"von Stebut E, Reich K, Tha\u00e7i D, et al.: Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Invest Dermatol 2019; 139: 1054–62.","DOI":"10.1016\/j.jid.2018.10.042"},{"key":"10.3238\/arztebl.m2024.0064_ref16","doi-asserted-by":"crossref","unstructured":"Langley RG, Poulin Y, Srivastava B, et al.: Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): a nested case-control analysis. J Am Acad Dermatol 2021; 84: 60–9.","DOI":"10.1016\/j.jaad.2020.08.032"},{"key":"10.3238\/arztebl.m2024.0064_ref17","doi-asserted-by":"crossref","unstructured":"Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU: Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol 2022; 18: 311–25.","DOI":"10.1038\/s41584-022-00776-6"},{"key":"10.3238\/arztebl.m2024.0064_ref18","doi-asserted-by":"crossref","unstructured":"Girolimetto N, Giovannini I, Crepaldi G, et al.: Psoriatic dactylitis: current perspectives and new insights in ultrasonography and magnetic resonance imaging. J Clin Med 2021; 10: 2604.","DOI":"10.3390\/jcm10122604"},{"key":"10.3238\/arztebl.m2024.0064_ref19","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Merola JF: Axial psoriatic arthritis: An update for dermatologists. J Am Acad Dermatol 2021; 84: 92–101.","DOI":"10.1016\/j.jaad.2020.05.089"},{"key":"10.3238\/arztebl.m2024.0064_ref20","doi-asserted-by":"crossref","unstructured":"Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982–6.","DOI":"10.1016\/0190-9622(95)91336-X"},{"key":"10.3238\/arztebl.m2024.0064_ref21","doi-asserted-by":"crossref","unstructured":"Najarian DJ, Gottlieb AB: Connections between psoriasis and Crohn‘s disease. J Am Acad Dermatol 2003; 48: 805–21; quiz 22–4.","DOI":"10.1067\/mjd.2003.540"},{"key":"10.3238\/arztebl.m2024.0064_ref22","doi-asserted-by":"crossref","unstructured":"Bellinato F, Gisondi P, Mantovani A, Girolomoni G, Targher G: Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies. J Endocrinol Invest 2022; 45: 1277–88.","DOI":"10.1007\/s40618-022-01755-0"},{"key":"10.3238\/arztebl.m2024.0064_ref23","doi-asserted-by":"crossref","unstructured":"Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Sch\u00e4fer I: Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633–6.","DOI":"10.1111\/j.1365-2133.2009.09593.x"},{"key":"10.3238\/arztebl.m2024.0064_ref24","doi-asserted-by":"crossref","unstructured":"Davis GK, Fehrenbach DJ, Madhur MS: Interleukin 17A: key player in the pathogenesis of hypertension and a potential therapeutic target. Curr Hypertens Rep 2021; 23: 13.","DOI":"10.1007\/s11906-021-01128-7"},{"key":"10.3238\/arztebl.m2024.0064_ref25","doi-asserted-by":"crossref","unstructured":"Wittenberg GM, Stylianou A, Zhang Y, et al.: Effects of immunomodulatory drugs on depressive symptoms: a mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Mol Psychiatry 2020; 25: 1275–85.","DOI":"10.1038\/s41380-019-0471-8"},{"key":"10.3238\/arztebl.m2024.0064_ref26","doi-asserted-by":"crossref","unstructured":"Mrowietz U, Dieckmann T, Gerdes S, Szymczak S, von Spreckelsen R, K\u00f6rber A: ActiPso: definition of activity types for psoriatic disease: a novel marker for an advanced disease classification. J Eur Acad Dermatol Venereol 2021; 35: 2027–33.","DOI":"10.1111\/jdv.17434"},{"key":"10.3238\/arztebl.m2024.0064_ref27","doi-asserted-by":"crossref","unstructured":"Maglio C, Peltonen M, Rudin A, Carlsson LMS: Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the swedish obese subjects study. Obesity (Silver Spring) 2017; 25: 2068–73.","DOI":"10.1002\/oby.21955"},{"key":"10.3238\/arztebl.m2024.0064_ref28","doi-asserted-by":"crossref","unstructured":"Egeberg A, S\u00f8rensen JA, Gislason GH, Knop FK, Skov L: Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery. JAMA Surg 2017; 152: 344–9.","DOI":"10.1001\/jamasurg.2016.4610"},{"key":"10.3238\/arztebl.m2024.0064_ref29","unstructured":"Zabotti A, De Marco G, Gossec L, et al.: EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Ann Rheum Dis 2023; 82: 1162–70."},{"key":"10.3238\/arztebl.m2024.0064_ref30","doi-asserted-by":"crossref","unstructured":"Vata D, Tarcau BM, Popescu IA, et al.: Update on obesity in psoriasis patients. Life (Basel) 2023; 13: 1947.","DOI":"10.3390\/life13101947"},{"key":"10.3238\/arztebl.m2024.0064_ref31","doi-asserted-by":"crossref","unstructured":"Sivasami P, Elkins C, Diaz-Saldana PP, et al.: Obesity-induced dysregulation of skin-resident PPARγ(+) Treg cells promotes IL-17A-mediated psoriatic inflammation. Immunity 2023; 56: 1844–61.e6.","DOI":"10.1016\/j.immuni.2023.06.021"},{"key":"10.3238\/arztebl.m2024.0064_ref32","doi-asserted-by":"crossref","unstructured":"Malavazos AE, Meregalli C, Sorrentino F, et al.: Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. Endocrinol Diabetes Metab Case Rep 2023; 2023: 23–0017.","DOI":"10.1530\/EDM-23-0017"},{"key":"10.3238\/arztebl.m2024.0064_ref33","doi-asserted-by":"crossref","unstructured":"Sommer R, Topp J, Mrowietz U, Zander N, Augustin M: Perception and determinants of stigmatization of people with psoriasis in the German population. J Eur Acad Dermatol Venereol 2020; 34: 2846–55.","DOI":"10.1111\/jdv.16436"},{"key":"10.3238\/arztebl.m2024.0064_ref34","doi-asserted-by":"crossref","unstructured":"Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M: Psoriasis: is the impairment to a patient‘s life cumulative? J Eur Acad Dermatol Venereol 2010; 24: 989–1004.","DOI":"10.1111\/j.1468-3083.2010.03705.x"},{"key":"10.3238\/arztebl.m2024.0064_ref35","doi-asserted-by":"crossref","unstructured":"Mrowietz U, Steinz K, Gerdes S: Psoriasis: to treat or to manage? Exp Dermatol 2014; 23: 705–9.","DOI":"10.1111\/exd.12437"},{"key":"10.3238\/arztebl.m2024.0064_ref36","doi-asserted-by":"crossref","unstructured":"Nast A, Altenburg A, Augustin M, et al.: Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm—Teil 1: Therapieziele und Therapieempfehlungen. J Dtsch Dermatol Ges 2021; 19: 934–51.","DOI":"10.1111\/ddg.14508_g"},{"key":"10.3238\/arztebl.m2024.0064_ref37","doi-asserted-by":"crossref","unstructured":"Sch\u00e4kel K, Reich K, Asadullah K, et al.: Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (‚clinical super response‘): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study. J Eur Acad Dermatol Venereol 2023; 37: 2016–27.","DOI":"10.1111\/jdv.19236"},{"key":"10.3238\/arztebl.m2024.0064_ref38","unstructured":"Coates LC, Soriano ER, Corp N, et al.: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022; 18: 465–79."},{"key":"10.3238\/arztebl.m2024.0064_ref39","doi-asserted-by":"crossref","unstructured":"Acosta Felquer ML, LoGiudice L, Galimberti ML, Rosa J, Mazzuoccolo L, Soriano ER: Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis. Ann Rheum Dis 2022; 81: 74–9.","DOI":"10.1136\/annrheumdis-2021-220865"},{"key":"10.3238\/arztebl.m2024.0064_ref40","doi-asserted-by":"crossref","unstructured":"Yee D, Kingston P, Lee K, et al.: Shared decision-making and satisfaction with care in patients with psoriasis: A population-based study in the United States. J Am Acad Dermatol 2023; 89: 920–6.","DOI":"10.1016\/j.jaad.2023.03.039"},{"key":"10.3238\/arztebl.m2024.0064_ref41","doi-asserted-by":"crossref","unstructured":"Piaserico S, Riedl E, Pavlovsky L, et al.: Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO). Front Med (Lausanne) 2023; 10: 1185523.","DOI":"10.3389\/fmed.2023.1185523"},{"key":"10.3238\/arztebl.m2024.0064_ref42","doi-asserted-by":"crossref","unstructured":"Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982–6.","DOI":"10.1016\/0190-9622(95)91336-X"},{"key":"10.3238\/arztebl.m2024.0064_ref43","doi-asserted-by":"crossref","unstructured":"Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH: Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol 2013; 133: 2340–6.","DOI":"10.1038\/jid.2013.149"},{"key":"10.3238\/arztebl.m2024.0064_ref44","doi-asserted-by":"crossref","unstructured":"Svedbom A, Stahle M: The psoriasis area and severity index is an independent risk factor for cardiovascular events: a prospective register study. J Eur Acad Dermatol Venereol 2023; 37: 1841–7.","DOI":"10.1111\/jdv.19168"},{"key":"10.3238\/arztebl.m2024.0064_ref45","doi-asserted-by":"crossref","unstructured":"Gao N, Kong M, Li X, et al.: The association between psoriasis and risk of cardiovascular disease: a mendelian randomization analysis. Front Immunol 2022; 13: 918224.","DOI":"10.3389\/fimmu.2022.918224"},{"key":"10.3238\/arztebl.m2024.0064_ref46","doi-asserted-by":"crossref","unstructured":"Faustini F, Simon D, Oliveira I, et al.: Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis. Ann Rheum Dis 2016; 75: 2068–74.","DOI":"10.1136\/annrheumdis-2015-208821"},{"key":"10.3238\/arztebl.m2024.0064_ref47","doi-asserted-by":"crossref","unstructured":"Chen ZT, Chen RF, Li XL, et al.: The role of ultrasound in screening subclinical psoriatic arthritis in patients with moderate to severe psoriasis. Eur Radiol 2023; 33: 3943–53.","DOI":"10.1007\/s00330-023-09493-4"},{"key":"10.3238\/arztebl.m2024.0064_ref48","doi-asserted-by":"crossref","unstructured":"Braun J, Wassenberg S: [Outcome parameters for use in psoriatic arthritis]. Z Rheumatol 2006; 65: 110, 2–8, 20–3.","DOI":"10.1007\/s00393-006-0046-3"},{"key":"10.3238\/arztebl.m2024.0064_ref49","doi-asserted-by":"crossref","unstructured":"Gladman DD: Axial disease in psoriatic arthritis. Curr Rheumatol Rep 2007; 9: 455–60.","DOI":"10.1007\/s11926-007-0074-2"},{"key":"10.3238\/arztebl.m2024.0064_ref50","doi-asserted-by":"crossref","unstructured":"Wolk K, Mallbris L, Larsson P, Rosenblad A, Ving\u00e5rd E, Stahle M: Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492–7.","DOI":"10.2340\/00015555-0711"},{"key":"10.3238\/arztebl.m2024.0064_ref51","doi-asserted-by":"crossref","unstructured":"Kim BR, Choi SW, Choi CW, et al.: Risk of uveitis in patients with psoriasis in Korea: a nationwide population-based cohort study. J Eur Acad Dermatol Venereol 2023; 37: 1336–43.","DOI":"10.1111\/jdv.19060"},{"key":"10.3238\/arztebl.m2024.0064_ref52","doi-asserted-by":"crossref","unstructured":"Duvetorp A, Mrowietz U, Nilsson M, Seifert O: Sex and age influence the associated risk of depression in patients with psoriasis: a retrospective population study based on diagnosis and drug-use. Dermatology 2021; 237: 595–602.","DOI":"10.1159\/000509732"},{"key":"10.3238\/arztebl.m2024.0064_ref53","doi-asserted-by":"crossref","unstructured":"Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U: Leptin, adiponectin, visfatin and retinol-binding protein-4—mediators of comorbidities in patients with psoriasis? Exp Dermatol 2012; 21: 43–7.","DOI":"10.1111\/j.1600-0625.2011.01402.x"},{"key":"10.3238\/arztebl.m2024.0064_ref54","doi-asserted-by":"crossref","unstructured":"Timis TL, Beni L, Mocan T, Florian IA, Orasan RI: Biologic therapies decrease disease severity and improve depression and anxiety symptoms in psoriasis patients. Life (Basel) 2023; 13:1219.","DOI":"10.3390\/life13051219"},{"key":"10.3238\/arztebl.m2024.0064_ref55","doi-asserted-by":"crossref","unstructured":"Ceovic R, Mance M, Bukvic Mokos Z, et al.: Psoriasis: female skin changes in various hormonal stages throughout life—puberty, pregnancy, and menopause. Biomed Res Int 2013; 2013: 571912.","DOI":"10.1155\/2013\/571912"},{"key":"10.3238\/arztebl.m2024.0064_ref56","doi-asserted-by":"crossref","unstructured":"Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401–7.","DOI":"10.1016\/S0190-9622(99)70112-X"},{"key":"10.3238\/arztebl.m2024.0064_ref57","doi-asserted-by":"crossref","unstructured":"Sommer R, Westphal L, Mrowietz U, Gerdes S, Augustin M: Measuring well-being in psoriasis: psychometric properties of the WHO-5 questionnaire. J Eur Acad Dermatol Venereol 2022; 36: e986-e7.","DOI":"10.1111\/jdv.18396"},{"key":"10.3238\/arztebl.m2024.0064_ref58","doi-asserted-by":"crossref","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al.: Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395: 1115–25.","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"10.3238\/arztebl.m2024.0064_ref59","doi-asserted-by":"crossref","unstructured":"McInnes IB, Asahina A, Coates LC, et al.: Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). Lancet 2023; 401: 25–37.","DOI":"10.1016\/S0140-6736(22)02302-9"},{"key":"10.3238\/arztebl.m2024.0064_ref60","doi-asserted-by":"crossref","unstructured":"Mrowietz U, Szepietowski JC, Loewe R, et al.: Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm(\u00ae)—and placebo-controlled trial (BRIDGE). Br J Dermatol 2017; 176: 615–23.","DOI":"10.1111\/bjd.14947"},{"key":"10.3238\/arztebl.m2024.0064_ref61","doi-asserted-by":"crossref","unstructured":"Warren RB, Mrowietz U, von Kiedrowski R, et al.: An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 528–37.","DOI":"10.1016\/S0140-6736(16)32127-4"},{"key":"10.3238\/arztebl.m2024.0064_ref62","doi-asserted-by":"crossref","unstructured":"Papp K, Reich K, Leonardi CL, et al.: Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37–49.","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"10.3238\/arztebl.m2024.0064_ref63","doi-asserted-by":"crossref","unstructured":"Paul C, Cather J, Gooderham M, et al.: Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173: 1387–99.","DOI":"10.1111\/bjd.14164"},{"key":"10.3238\/arztebl.m2024.0064_ref64","doi-asserted-by":"crossref","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al.: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 2023; 88: 29–39.","DOI":"10.1016\/j.jaad.2022.07.002"},{"key":"10.3238\/arztebl.m2024.0064_ref65","doi-asserted-by":"crossref","unstructured":"Strober B, Tha\u00e7i D, Sofen H, et al.: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. J Am Acad Dermatol 2023; 88: 40–51.","DOI":"10.1016\/j.jaad.2022.08.061"},{"key":"10.3238\/arztebl.m2024.0064_ref66","doi-asserted-by":"crossref","unstructured":"Menter A, Tyring SK, Gordon K, et al.: Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106–15.","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"10.3238\/arztebl.m2024.0064_ref67","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Blauvelt A, Tha\u00e7i D, et al.: Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol 2018; 79: 302–14.e6.","DOI":"10.1016\/j.jaad.2018.04.012"},{"key":"10.3238\/arztebl.m2024.0064_ref68","doi-asserted-by":"crossref","unstructured":"Papp KA, Tyring S, Lahfa M, et al.: A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304–12.","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"10.3238\/arztebl.m2024.0064_ref69","doi-asserted-by":"crossref","unstructured":"Reich K, Nestle FO, Papp K, et al.: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367–74.","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"10.3238\/arztebl.m2024.0064_ref70","doi-asserted-by":"crossref","unstructured":"Gordon KB, Foley P, Krueger JG, et al.: Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet 2021; 397: 475–86.","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"10.3238\/arztebl.m2024.0064_ref71","doi-asserted-by":"crossref","unstructured":"Papp KA, Reich K, Paul C, et al.: A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175: 273–86.","DOI":"10.1111\/bjd.14493"},{"key":"10.3238\/arztebl.m2024.0064_ref72","doi-asserted-by":"crossref","unstructured":"Gordon KB, Blauvelt A, Papp KA, et al.: Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375: 345–56.","DOI":"10.1056\/NEJMoa1512711"},{"key":"10.3238\/arztebl.m2024.0064_ref73","doi-asserted-by":"crossref","unstructured":"Langley RG, Elewski BE, Lebwohl M, et al.: Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med 2014; 371: 326–38.","DOI":"10.1056\/NEJMoa1314258"},{"key":"10.3238\/arztebl.m2024.0064_ref74","doi-asserted-by":"crossref","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al.: Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665–74.","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"10.3238\/arztebl.m2024.0064_ref75","doi-asserted-by":"crossref","unstructured":"Papp KA, Langley RG, Lebwohl M, et al.: Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675–84.","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"10.3238\/arztebl.m2024.0064_ref76","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al.: Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76: 405–17.","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"10.3238\/arztebl.m2024.0064_ref77","doi-asserted-by":"crossref","unstructured":"Reich K, Armstrong AW, Foley P, et al.: Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76: 418–31.","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"10.3238\/arztebl.m2024.0064_ref78","doi-asserted-by":"crossref","unstructured":"Gordon KB, Strober B, Lebwohl M, et al.: Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392: 650–61.","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"10.3238\/arztebl.m2024.0064_ref79","doi-asserted-by":"crossref","unstructured":"Reich K, Papp KA, Blauvelt A, et al.: Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390: 276–88.","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"10.3238\/arztebl.m2024.0064_ref80","doi-asserted-by":"crossref","unstructured":"Graier T, Weger W, Jonak C, et al.: Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep 2022; 12: 15078.","DOI":"10.1038\/s41598-022-18790-9"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T09:57:41Z","timestamp":1720087061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2024.0064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":80,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2024.0064","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}